| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/07/2011 | US20110081342 Anti-vegf antibodies |
| 04/07/2011 | US20110081341 Immunopotentiative composition |
| 04/07/2011 | US20110081340 Methods for treating disease using an anti-il-21 receptor antibody |
| 04/07/2011 | US20110081339 Methods of using il-17 receptor a antibodies |
| 04/07/2011 | US20110081338 Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation |
| 04/07/2011 | US20110081337 Function of gpr4 in vascular inflammatory response to acidosis and related methods |
| 04/07/2011 | US20110081316 Pyrazole inhibitors of phosphatidylinositol 3-kinase |
| 04/07/2011 | US20110081312 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| 04/07/2011 | US20110081311 Complexes of il-15 and il-15ralpha and uses thereof |
| 04/07/2011 | US20110081295 Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration |
| 04/07/2011 | US20110081292 Methods Of Treating Viral Hepatitis |
| 04/07/2011 | DE102010018462A1 Impfstoffe zum Schutz gegen Influenza Vaccines to protect against influenza |
| 04/07/2011 | CA2779506A1 Methods of improving vaccine immunogenicity |
| 04/07/2011 | CA2776472A1 Microparticle compositions and methods for treating age-related macular degeneration |
| 04/07/2011 | CA2776413A1 Adjuvanted vaccine formulations |
| 04/07/2011 | CA2776386A1 Piscine reovirus immunogenic compositions |
| 04/07/2011 | CA2776271A1 Anti-hsv antibody |
| 04/07/2011 | CA2776195A1 Hepatitis c virus vaccine composition |
| 04/07/2011 | CA2776144A1 Influenza hemagglutinin antibodies, compositions, and related methods |
| 04/07/2011 | CA2776037A1 Anti-fibroblast activation protein antibodies and methods and uses thereof |
| 04/07/2011 | CA2776022A1 Antibodies that specifically bind to the epha2 receptor |
| 04/07/2011 | CA2775846A1 T-cell receptor capable of recognising an antigen from cytomegalovirus |
| 04/07/2011 | CA2775810A1 Endoglin antibodies |
| 04/07/2011 | CA2775794A1 Formulation of hepatitis b virus antigens for cellular stimulation followed by therapeutic immunization |
| 04/07/2011 | CA2775761A1 Combination immunotherapy for the treatment of cancer |
| 04/07/2011 | CA2775720A1 Peptides for inducing heterosubtypic influenza t cell responses |
| 04/07/2011 | CA2774559A1 Novel vaccine composition |
| 04/07/2011 | CA2774552A1 Drug fusions and conjugates with extended half life |
| 04/07/2011 | CA2774256A1 Monoclonal antibodies |
| 04/07/2011 | CA2766418A1 Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| 04/06/2011 | EP2305836A1 Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer |
| 04/06/2011 | EP2305827A1 Cancer antigen MAGE-A9 and uses thereof |
| 04/06/2011 | EP2305822A2 Methods and compositions for diseases associated with Amyloidosis |
| 04/06/2011 | EP2305818A2 Antigen constructs useful in the detection and differentiation of antibodies to HIV |
| 04/06/2011 | EP2305817A2 Anti-IL-12 antibodies, compositions, methods and uses |
| 04/06/2011 | EP2305816A1 Mutation in the Parkin gene, compositions, methods and uses |
| 04/06/2011 | EP2305716A2 Antibodies directed to gpnmb and uses thereof |
| 04/06/2011 | EP2305715A2 Monoclonal antibody to osteoprotegerin binding protein |
| 04/06/2011 | EP2305714A2 Anti-interferon-alpha subtypes antibodies |
| 04/06/2011 | EP2305713A1 Human antibodies that bind human TNFalpha |
| 04/06/2011 | EP2305712A1 Human antibodies that bind human TNFalpha |
| 04/06/2011 | EP2305711A2 Methods for treating osteoarthitis pain by administering a nerve growth factor antagonist and compositions containing the same |
| 04/06/2011 | EP2305708A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 04/06/2011 | EP2305707A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 04/06/2011 | EP2305706A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 04/06/2011 | EP2305701A1 Tuberculosis antigen detection assays and vaccines |
| 04/06/2011 | EP2305700A1 Therapeutic USPA1-derived peptides |
| 04/06/2011 | EP2305699A1 Stabilised mRNA with increased G/C content which is optimised for translation in its coded areas |
| 04/06/2011 | EP2305314A2 Remodelling and glycoconjugation of antibodies |
| 04/06/2011 | EP2305313A2 Remodelling and glycoconjugation of interferon-alpha (IFNa) |
| 04/06/2011 | EP2305312A2 Remodelling and glycoconjugation of follicle-stimulating hormone (FSH) |
| 04/06/2011 | EP2305311A2 Glycoconjugation of peptides |
| 04/06/2011 | EP2305306A1 Neuroinvasion inhibitor |
| 04/06/2011 | EP2305304A1 Immunopotentiating agent comprising ep1 agonist |
| 04/06/2011 | EP2305303A2 Immunization against Clostridium difficile disease |
| 04/06/2011 | EP2305302A2 Prevention and treatment of amyloidogenic disease |
| 04/06/2011 | EP2305301A2 Methods of diagnosing and treating pre-eclampsia or eclampsia |
| 04/06/2011 | EP2305300A1 Pharmaceutical composition for treatment and prevention of cancer |
| 04/06/2011 | EP2305299A1 Chimeric alphavirus replicon particles |
| 04/06/2011 | EP2305298A1 Vaccine against streptococcus pneumoniae |
| 04/06/2011 | EP2305297A1 Vaccine against streptococcus pneumoniae |
| 04/06/2011 | EP2305296A1 Immunogenic composition for use in vaccination against staphylococcei |
| 04/06/2011 | EP2305295A1 Immunogenic composition for use in vaccination against staphylococcei |
| 04/06/2011 | EP2305294A1 Immunogenic composition for use in vaccination against staphylococcei |
| 04/06/2011 | EP2305293A2 Immunization against Clostridium difficile disease |
| 04/06/2011 | EP2305292A1 S/o type transdermal immunizing agent |
| 04/06/2011 | EP2305286A2 Treatment for Alzeimer's disease |
| 04/06/2011 | EP2305282A2 Prevention and treatment of amyloidogenic disease |
| 04/06/2011 | EP2305277A1 Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis |
| 04/06/2011 | EP2305247A2 Methods for detecting and reversing resistance to macrocyclic lactone compounds |
| 04/06/2011 | EP2305245A1 Treatment of diseases associated with the use of antibiotics |
| 04/06/2011 | EP2305244A1 Treatment of diseases associated with the use of antibiotics |
| 04/06/2011 | EP2305027A2 Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| 04/06/2011 | EP2304053A1 Identification and use of prognostic and predictive markers in cancer treatment |
| 04/06/2011 | EP2304049A1 Method of treatment of vascular complications |
| 04/06/2011 | EP2304034A1 An adapter molecule for the delivery of adenovirus vectors |
| 04/06/2011 | EP2304024A2 Avian reoviridae |
| 04/06/2011 | EP2303926A1 Immunogenic memapsin 2 -secretase peptides and methods of use |
| 04/06/2011 | EP2303924A2 Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same |
| 04/06/2011 | EP2303923A1 Human cytomegalovirus neutralising antibodies and use thereof |
| 04/06/2011 | EP2303918A2 Methods for dosing an activin-actriia antagonist and monitoring of treated patients |
| 04/06/2011 | EP2303912A1 Cdca1 epitope peptides and vaccines containing the same |
| 04/06/2011 | EP2303909A1 Iqgap3 epitope peptides and vaccines containing the same |
| 04/06/2011 | EP2303407A1 Methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells |
| 04/06/2011 | EP2303325A2 Inhibition of emmprin to treat multiple sclerosis |
| 04/06/2011 | EP2303324A1 Immunogenic composition |
| 04/06/2011 | EP2303323A1 Modified beta-lactoglobulins for immunotherapy of milk allergy |
| 04/06/2011 | EP2303322A1 Recombinant modified vaccinia virus measles vaccine |
| 04/06/2011 | EP2303321A1 Combined influenza vaccines for seasonal and pandemic protection |
| 04/06/2011 | EP2303320A1 Attenuated pestivirus |
| 04/06/2011 | EP2303319A2 Compositions, methods and kits for eliciting an immune response |
| 04/06/2011 | EP2303318A2 Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains |
| 04/06/2011 | EP2303317A2 Compositions and methods of use of orf 554 from beta hemolytic streptococcal strains |
| 04/06/2011 | EP2303316A1 Constructing a dna chimera for vaccine development against leishmaniasis and tuberculosis |
| 04/06/2011 | EP2303315A1 Method for treating disease characterized by plaque |
| 04/06/2011 | EP2303312A2 Smallpox dna vaccine and the antigens therein that elicit an immune response |
| 04/06/2011 | EP2303296A2 Orally administerable vaccine for yersinia pestis |
| 04/06/2011 | EP2303263A1 Use |
| 04/06/2011 | EP2303236A2 Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors |
| 04/06/2011 | EP2303234A1 Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance |